Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $75.11 on Thursday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 16.19 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The company has a 50 day simple moving average of $81.00 and a 200-day simple moving average of $79.11. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter last year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $28,000. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Hantz Financial Services Inc. lifted its holdings in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $50,000. 76.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on ANIP shares. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Guggenheim reduced their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday. Finally, Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.